Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease

Jeffrey R. Marks, Karen Anderson, Paul Engstrom, Andrew K. Godwin, Laura J. Esserman, Gary Longton, Edwin S. Iversen, Anu Mathew, Christos Patriotis, Margaret S. Pepe

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.

Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.

Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.

Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.

Impact: Availability of prospectively collected samples should improve future validation efforts.

Original languageEnglish (US)
Pages (from-to)435-441
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Breast Neoplasms
Biomarkers
Research
Neoplasms
Credentialing
Breast Diseases
Carcinoma in Situ
Mammography
Immunoassay
Estrogen Receptors
Breast
Research Personnel
Pathology
Serum
Proteins

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. / Marks, Jeffrey R.; Anderson, Karen; Engstrom, Paul; Godwin, Andrew K.; Esserman, Laura J.; Longton, Gary; Iversen, Edwin S.; Mathew, Anu; Patriotis, Christos; Pepe, Margaret S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 2, 01.02.2015, p. 435-441.

Research output: Contribution to journalArticle

Marks, JR, Anderson, K, Engstrom, P, Godwin, AK, Esserman, LJ, Longton, G, Iversen, ES, Mathew, A, Patriotis, C & Pepe, MS 2015, 'Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease', Cancer Epidemiology Biomarkers and Prevention, vol. 24, no. 2, pp. 435-441. https://doi.org/10.1158/1055-9965.EPI-14-1178
Marks, Jeffrey R. ; Anderson, Karen ; Engstrom, Paul ; Godwin, Andrew K. ; Esserman, Laura J. ; Longton, Gary ; Iversen, Edwin S. ; Mathew, Anu ; Patriotis, Christos ; Pepe, Margaret S. / Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. In: Cancer Epidemiology Biomarkers and Prevention. 2015 ; Vol. 24, No. 2. pp. 435-441.
@article{c8f3b4831bbb4b4797382becb735b940,
title = "Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease",
abstract = "Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.Impact: Availability of prospectively collected samples should improve future validation efforts.",
author = "Marks, {Jeffrey R.} and Karen Anderson and Paul Engstrom and Godwin, {Andrew K.} and Esserman, {Laura J.} and Gary Longton and Iversen, {Edwin S.} and Anu Mathew and Christos Patriotis and Pepe, {Margaret S.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1158/1055-9965.EPI-14-1178",
language = "English (US)",
volume = "24",
pages = "435--441",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease

AU - Marks, Jeffrey R.

AU - Anderson, Karen

AU - Engstrom, Paul

AU - Godwin, Andrew K.

AU - Esserman, Laura J.

AU - Longton, Gary

AU - Iversen, Edwin S.

AU - Mathew, Anu

AU - Patriotis, Christos

AU - Pepe, Margaret S.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.Impact: Availability of prospectively collected samples should improve future validation efforts.

AB - Background: Many circulating biomarkers have been reported for the diagnosis of breast cancer, but few, if any, have undergone rigorous credentialing using prospective cohorts and blinded evaluation.Methods: The NCI Early Detection Research Network (EDRN) has created a prospective, multicenter collection of plasma and serum samples from 832 subjects designed to evaluate circulating biomarkers for the detection and diagnosis of breast cancer. These samples are available to investigators who wish to evaluate their biomarkers using a set of blinded samples. The breast cancer reference set is composed of blood samples collected using a standard operating procedure at four U.S. medical centers from 2008 to 2010 from women undergoing either tissue diagnosis for breast cancer or routine screeningmammography. The reference set contains samples from women with incident invasive cancer (n=190), carcinoma in situ (n=55), benign pathology with atypia (n=63), benign disease withno atypia (n=231), andwomenwith no evidence of breast disease by screening mammography (BIRADS 1 or 2, n=276). Using a subset of plasma samples (n=505) from the reference set, we analyzed 90 proteins by multiplexed immunoassays for their potential utility as diagnostic markers.Results: We found that none of these markers is useful for distinguishing cancer from benign controls. However, elevated CA-125 does appear to be a candidate marker for estrogen receptor-negative cancers.Conclusions: Markers that can distinguish benign breast conditions from invasive cancer have not yet been found.Impact: Availability of prospectively collected samples should improve future validation efforts.

UR - http://www.scopus.com/inward/record.url?scp=84922724941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922724941&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-14-1178

DO - 10.1158/1055-9965.EPI-14-1178

M3 - Article

VL - 24

SP - 435

EP - 441

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -